Eltrombopag. Antithrombocytopenic, thrombopoietin receptor agonist

Drugs of the Future

Volumn 31, Issue 9, 2006, Pages 767-770

  Revill, P ^a   Serradell, N ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3' [2 [1 (3,4 DIMETHYLPHENYL) 3 METHYL 5 OXO 4,5 DIHYDRO 1H PYRAZOL 4 YLIDENE]HYDRAZINO] 2' HYDROXYBIPHENYL 3 CARBOXYLIC ACID; ELTROMBOPAG; PEGINTERFERON; PLACEBO; PROMACTA; RECOMBINANT THROMBOPOIETIN; RIBAVIRIN; THROMBOPOIETIN RECEPTOR;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEADACHE; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER DISEASE; MEGAKARYOCYTE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 33845298640     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.09.1030939     Document Type: Article

References (27)

1. Delorme, E.O., Duffy, K.J., Lamb, P.I., Luengo, J.I., Tian, S.-S.C. (GlaxoSmithKline Inc.; Ligand Pharmaceuticals, Inc.). Regulated activation of cell-membrane receptors by metalchelating agonists. CA 2432800, EP 1351979, JP 2004532614, WO 02057300.
2. Duffy, K., Erickson-Miller, C.L., Eppley, D.F. et al. (SmithKline Beecham Corp.; Glaxo Group, Ltd.). Thrombopoietin mimetics. WO 0189457.
3. Kaushansky, K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005, 115(12): 3339-47.
4. Kuter, D.J., Begley, C.G. Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood 2002, 100(10): 3457-69.
5. Luengo, J.I., Duffy, K.J., Shaw, A.N. et al. Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood 2004, 104(11, Part I): Abst 2910.
6. Erickson-Miller, C.L., Delorme, E., Tian, S.-S. et al. In vitro biological activity of SB-497115, an orally bioavailable, small molecule platelet growth factor. Eur J Cancer - Suppl [13th Eur Cancer Conf (ECCO) (Oct 30-Nov 3, Paris) 2005] 2005, 3(2): Abst 170.
7. Erickson-Miller, C.L., Luengo, J.I., Nicholl, R. et al. In vitro and in vivo biology of a small molecular weight Tpo receptor agonist, SB-497115. 96th Annu Meet Am Assoc Cancer Res (AACR) (April 16-20, Anaheim) 2005, Abst 2565.
8. Erickson-Miller, C., Delorme, E., Giampa, L. et al. Biological activity and selectivity for Tpo receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115. Blood 2004, 104(11, Part 1): Abst 2912.
9. Erickson-Miller, C.L., Delorme, E., Iskandar, M. et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood 2004, 104(11, Part 1): Abst 2909.
10. Erickson-Miller, C.L., Tian, S.-S., Hopson, C. et al. Species specificity and receptor domain interaction of a small molecule Tpo receptor agonist, SB-497115. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 4929.
11. Sellers, T., Hart, T., Semanik, M., Murthy, K. Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs. Blood 2004, 104(11, Part 1): Abst 2063.
12. Erhardt, J., Tapley, P., Erickson-Miller, C.L. A low molecular weight, orally active TPOR agonist, SB-497115, does not prime platelets for activation or agonist-induced aggregation in vitro. Exp Hematol [34th Annu Sci Meet Int Soc Exp Hematol (July 30-Aug 2, Glasgow) 2005] 2005, 33(7, Suppl. 1): Abst 365.
13. Erhardt, J., Abboud, M., Toomey, J., Erickson-Miller, C.L. The low molecular weight TpoR agonist, eltrombopag, does not prime platelet activation in vitro. 11th Congr Eur Hematol Assoc (June 15-18, Amsterdam) 2006, Abst 1024.
14. Erhardt, J., Erickson-Miller, C.L., Tapley, P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood 2004, 104(11, Part 2): Abst 3888.
15. Jenkins, J., Nicholl, R., Williams, D. et al. An oral, non-peptide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects. Blood 2004, 104(11, Part 1): Abst 2916.
16. Jenkins, J., Williams, D., Collins, D.A., Kitchen, V., Deng, Y., Erickson-Miller, C. SB-497115, a novel, oral, small molecule thrombopoietin receptor agonist, increases platelet counts in healthy subjects. 11th Annu FDA Sci Forum (April 27-28, Washington, D.C.) 2005, Abst C-07.
17. Jenkins, J., Williams, D., Collins, D.A., Deng, Y., Kitchen, V., Uhl, J., Erickson-Miller, C. SB-497115, a novel, oral platelet growth factor, increases platelet counts in healthy subjects. Eur J Cancer - Suppl [13th Eur Cancer Conf (ECCO) (Oct 30-Nov 3, Paris) 2005] 2005, 3(2): Abst 1453.
18. Jenkins, J., Williams, D., Collins, D.A., Deng, Y., Kitchen, V., Erickson-Miller, C. SB-497115, a novel, oral, small molecule thrombopoietin receptor agonist, increases platelet counts in healthy subjects. Exp Hematol [34th Annu Sci Meet Int Soc Exp Hematol (July 30-Aug 2, Glasgow) 2005] 2005, 33(7, Suppl. 1): Abst 105.
19. Provan, D., Saleh, M., Goodison, S. et al. The safety profile of eltrombopag, a novel, oral platelet growth factor, in thrombocytopenic patients and healthy subjects. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 18596.
20. Bussel, J., Saleh, M., Provan, D. et al. Eltrombopag, a novel, oral platelet growth factor, increases platelet counts in thrombocytopenic patients and healthy subjects. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 8602.
21. Newland, A., Stone, N., Cheng, G. et al. Eltrombopag increases platelets during 6-week treatment of ITP - Results of a randomized, double-blind, placebo-controlled phase II study. 11th Congr Eur Hematol Assoc (June 15-18, Amsterdam) 2006, Abst 1022.
22. EXTEND (Eltrombopag eXTENded Dosing Study) (NCT00351468). ClinicalTrials.gov Web site 2006.
23. SB-497115 (oral thrombopoietin receptor agonist) versus placebo in adults with refractory immune thrombocytopenic purpura (ITP) (NCT00102739). ClinicalTrials.gov Web site 2006.
24. McHutchinson, J.J.G., Afdhal, N. Schiffman, M.L. et al. Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV associated thrombocytopenia: Preliminary results from a phase II dose-ranging study. 41st Annu Meet Eur Assoc Study Liver (April 26-30, Vienna) 2006, Abst 745.
25. SB-497115 (oral thrombopoietin receptor agonist) versus placebo in adults with thrombocytopenia due to hepatitis C (NCT00110799). ClinicalTrials.gov Web site 2006.
26. SB-497115 (oral thrombopoietin receptor agonist) versus placebo in adult cancer patients receiving chemotherapy (NCT00102726). ClinicalTrials.gov Web site 2006.
27. Dose evaluation study of oral eltrombopag in patients with sarcoma receiving the adriamycin and ifosfamide regimen (NCT00358540). ClinicalTrials.gov Web site 2006.